Alerts will be sent to your verified email
Verify EmailBALAXI
|
Balaxi Pharma.
|
Alpa Lab
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
28.02 % | 10.02 % | 0.0 |
|
5yr average Equity Multiplier
|
1.4 | 1.26 | 1.68 |
|
5yr Average Asset Turnover Ratio
|
1.43 | 0.62 | 0.62 |
|
5yr Avg Net Profit Margin
|
11.03 % | 13.26 % | -21.45 % |
|
Price to Book
|
0.57 | 0.79 | 1.25 |
|
P/E
|
14.32 | 12.33 | 6.71 |
|
5yr Avg Cash Conversion Cycle
|
154.28 Days | 114.37 Days | 23.75 Days |
|
Inventory Days
|
87.41 Days | 51.33 Days | 83.11 Days |
|
Days Receivable
|
103.86 Days | 142.78 Days | 80.26 Days |
|
Days Payable
|
63.18 Days | 94.49 Days | 163.46 Days |
|
5yr Average Interest Coverage Ratio
|
57.05 | 94.43 | -11.18 |
|
5yr Avg ROCE
|
36.52 % | 13.16 % | -11.18 % |
|
5yr Avg Operating Profit Margin
|
16.64 % | 7.55 % | -10.26 % |
|
5 yr average Debt to Equity
|
0.09 | 0.02 | 0.18 |
|
5yr CAGR Net Profit
|
-5.76 % | 21.88 % | -12.45 % |
|
5yr Average Return on Assets
|
18.47 % | 7.94 % | -13.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
65.99 % | 57.19 % | 52.62 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-5.58 % | -0.1 % | -13.79 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 9.9 % |
|
Balaxi Pharma.
|
Alpa Lab
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
-
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|